Keymed Biosciences Inc(2162) News

Date	Title
Aug 27	Keymed Biosciences Announces Interim Results for First Half of 2024
Jun 20	Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM